Form 4: Madrigal Pharmaceuticals Director James M. Daly Reports Stock Transactions
SEC Form 4 Filing
Director James M. Daly of Madrigal Pharmaceuticals reports the exercise of stock options and subsequent sale of common stock on February 27, 2025.
Summary
- On February 27, 2025, James M. Daly, a director of Madrigal Pharmaceuticals, executed stock options to acquire 9,470 shares at $65.06 and 6,000 shares at $111.06.
- Following the acquisition of these shares, Daly sold 398 shares at a weighted average price of $346.9031, 14,302 shares at $347.39, and 770 shares at $348.9433.
- After these transactions, Daly directly owns 1,912 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment about the company's performance.
Industry Context
This Form 4 filing is a routine disclosure of stock transactions by a company insider. It provides transparency to the market regarding the buying and selling activities of company directors.
Stakeholder Impact
- The transactions may provide information to shareholders regarding insider sentiment, but the impact is likely minimal given the relatively small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| 02/27/2025 | Date of earliest transaction: stock option exercise and stock sales. |
| 02/28/2025 | Date of signature on the Form 4 filing. |
| 06/16/2025 | Expiration date of one of the stock option grants. |
| 06/17/2025 | Expiration date of one of the stock option grants. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.